STAT October 8, 2024
The need-to-know this morning
- Astellas licensed an experimental gene therapy from privately held AviadoBio for the treatment of frontotemporal dementia and other related indications.
- Sage Therapeutics said Sage-718 failed to improve cognition relative to a placebo in a mid-stage study involving patients with early-stage Alzheimer’s disease.
John Maraganore’s next-generation RNAi startup
John Maraganore, the former CEO of Alnylam, is launching a new startup with $135 million from ARCH Venture Partners, Fidelity, Invus, Rock Springs Capital, Regeneron Ventures, and others, he told STAT exclusively.
The new company, called City Therapeutics, is developing new drugs that use RNA interference to silence genes and halt the production of harmful proteins. That’s a familiar area for Maraganore: Alnylam won regulatory approval of...
Today's Sponsors
Today's Sponsor